Clinical Drug Experience Knowledgebase

VASCULERA (diosmiplex) consists of diosmin glycoside in combination with alkaline granules, alka4-complex. Alka4-complex contains 30 mg of a proprietary, structured, highly alkaline agglomeration of reactive magnesium hydroxide (Mg(OH)2, molecular weight 58.3), potassium chloride (KCl, molecular weight 74.6) and potassium hydroxide (KOH, molecular weight 56.1) held apart from each other in a matrix of calcium carbonate (CaCO3, molecular weight 100.1), microcrystalline cellulose and croscarmellose sodium. VASCULERA is indicated for the clinical dietary management of the metabolic processes associated with chronic venous insufficiency (CVI). VASCULERA acts by restoring toward normal the metabolic aspects of CVI including modulation of venous tone and capillary resistance, management of lymphatic drainage, and inflammation in the microcirculation. Alka4-complex has been shown in preclinical and clinical studies to act as an acid buffering agent in the gut and to counteract the effects of increased acid production systemically. Clinical studies have shown that alka4-complex in VASCULERA can reduce acidosis under extreme exercise loads. The specially agglomerated matrix of alka4-complex has been shown to resist neutralization by acid solutions. In addition, the alka4-complex has been shown to reduce the acid producing effects of certain foods by buffering the acidity in the gastrointestinal tract, while allowing a sufficient portion of the complex to survive in the stomach, and is absorbed in the small intestine thereby being available to manage mild acidosis.   ^NCATS